Back to search
Multiple System Atrophy - Parkinsonian Subtype (MSA-P)
Clinical trial pipeline · Data from ClinicalTrials.gov
See which Multiple System Atrophy - Parkinsonian Subtype (MSA-P) trials you may qualify forClinical trial pipeline · Data from ClinicalTrials.gov
See which Multiple System Atrophy - Parkinsonian Subtype (MSA-P) trials you may qualify forThis clinical trial is designed to evaluate the safety, tolerability and preliminary efficacy of a single injection of NouvNeu001 (Human Dopaminergic Progenitor…
This study is an observational, prospective genetic study. It aims to obtain DNA for research and testing from patients with PSP, CBS, MSA, and related neurolog…
The PD-HemON study aims to evaluate the safety and preliminary efficacy of ARC-IM Therapy (Epidural Electrical Stimulation) to support hemodynamic management in…
This is a single-center, prospective, randomized, open-label, blinded outcome assessment (PROBE) study. At the end of the PROBE study, patients who have complet…
The aim of this study was to apply PET/MR techniques targeting TSPO to explore the temporal and spatial alterations characterizing neuroinflammation in MSA pati…
The aim of this study was to apply the targeted α-synuclein PET study technique to investigate the pathological load and spatial distribution characteristics of…
Multiple system atrophy (MSA) is a disorder of the nervous system of unclear cause. In MSA there is degeneration (progressive loss) of nerve cells in several br…